Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab

OBJECTIVE: Patients with HER2-positive metastatic breast cancer (MBC) benefit from trastuzumab-based therapy but eventually develop intrinsic or acquired resistance. Whether plasma HER2 gene copy number (GCN) could predict survival after trastuzumab treatment remained controversial. We evaluated the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Principais autores: Ran, Ran, Huang, Wenfa, Liu, Yaxin, Shao, Lin, Liu, Xiaoran, Niu, Yunyun, Kong, Weiyao, Bo, Shiping, Rugo, Hope S, Lu, Sijia, Li, Huiping
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7245474/
https://ncbi.nlm.nih.gov/pubmed/32547071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S240990
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados